沃顿氏间充质干细胞来源EVs作为天然纳米颗粒通过miRNA调节减轻软骨损伤
核心信息
- 论文英文标题: Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via microRNA regulation
- 期刊: INT J PHARMACEUT
- 发表年份: 2022
- DOI: 10.1016/j.ijpharm.2022.121952
- PMID/PMCID: 35753534
研究概览
The main strategy of tissue repair and regeneration focuses on the application of mesenchymal stem cells and cell-based nanoparticles, but there are still multiple challenges that may have negative impacts on human safety and therapeutic efficacy. Our findings suggest that WJMSC-sEV-induced chondrogenesis is a promising innovative and feasible cell-free nanotherapy for OA treatment.
核心发现
The main strategy of tissue repair and regeneration focuses on the application of mesenchymal stem cells and cell-based nanoparticles, but there are still multiple challenges that may have negative impacts on human safety and therapeutic efficacy.
Cell-free nanotechnology can effectively overcome these obstacles and limitations.
Mesenchymal stem cell (MSC)-derived natural small extracellular vesicles (sEVs) represent ideal nanotherapeutics due to their low immunogenicity and lack of tumorigenicity.
Here, sEVs harvested from Wharton's jelly mesenchymal stem cells (WJMSCs) were identified.
Echo Biotech 角色
外泌体miRNA测序
关联平台: Exoomics®, Research Reagents & Tools
关联服务与能力: EV Isolation & Purification, EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
关联产品或试剂: Exosupur® EV Isolation/Purification Kit
参考文献
原始论文: Wharton's jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via microRNA regulation International journal of pharmaceutics. 2022. DOI: 10.1016/j.ijpharm.2022.121952. PMID/PMCID: 35753534.